IV adenosine
PreclinicalSmall molecule
IV adenosine is one of 9 small molecule programs targeting Supraventricular tachycardia. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Supraventricular Tachycardia
#DrugCompanyPhaseTrials
1Cordarone
WWyeth-Lederle Vaccines
Approved
Lanoxin
AAdvanz Pharma
Phase 3
Betapace
LLegacy Health System
Phase 3
Inderal
WWyeth-Lederle Vaccines
Phase 3
Adenocard
AstellasPreclinical
Tambocor
AAlvogen Korea
Preclinical
Calan
VVal Adams
Preclinical
Dexmedetomidine, Midazolam
NNational Taiwan University Hospital
Preclinical
IV adenosine
UUniversity of Iowa
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IV adenosine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Iowa